Preventing CMV in kidney transplant patients with specific therapies
Official title: Kidney transplant Preemptive therapy or Prophylaxis (KPoP) for CMVPreventionin D+R- Recipients
Funded at University of California, San Francisco · NIH-11137566 · Data updated 2026-11-12
This study is looking at how to better protect kidney transplant patients who haven't had cytomegalovirus (CMV) before, but are getting a kidney from someone who has, by comparing two ways of preventing CMV: taking medicine for a while or waiting to see if they get sick before treating them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | July 12, 2024 |
| Project end | May 31, 2031 |
| Funding year | 2025 |
| Award (this year) | $1,698,522 |
| NIH project number | 5R01AI184205-03 |
| Project ID | NIH-11137566 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are kidney transplant recipients who are CMV seronegative and have received an organ from a CMV seropositive donor.
✕Less likely to help
Patients who are not undergoing kidney transplantation or those who are CMV seropositive may not benefit from this research.
What this research studies
This research focuses on improving the prevention of cytomegalovirus (CMV) in kidney transplant recipients who are seronegative for CMV and receive an organ from a seropositive donor. The study compares two approaches: antiviral prophylaxis, which involves taking antiviral medication for a set period, and preemptive therapy, where patients are monitored for CMV and treated only if necessary. The goal is to enhance the immune response against CMV while reducing the duration of antiviral medication. By understanding the effectiveness of these strategies, the research aims to improve patient outcomes and reduce complications related to CMV.
Why it matters
Potential benefit: If successful, this research could significantly reduce the incidence of CMV-related complications in kidney transplant recipients, leading to better overall health and graft survival.
How similar studies have gone: Previous research in liver transplant patients has shown that preemptive therapy can be effective, but this approach has not been extensively tested in kidney transplant recipients.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Limaye, Abhijit Prakash — University of California, San Francisco
- Study coordinator: Limaye, Abhijit Prakash
Related research
Other NIH-funded projects on the same topics.
-
Microbial clues to diagnose and predict infections in kidney transplant patients
A patient-focused project will look for microbial biomarkers in stool, blood, and urine to help doctors predict and diagnose infections in people who have had a kidney transplant.
-
Immunological mechanisms behind treatment-resistant kidney transplant rejection
This grant explores why certain kidney transplant rejections don’t respond to standard treatments and what immune cells in the graft are driving that resistance.
-
Complement-Bound Exosomes and Kidney Transplant Immunity
This project studies how kidney transplant injury and rejection happen after surgery and whether blocking certain immune pathways during organ preservation could improve transplant outcomes.
-
Blood vessel signals predicting heart problems after kidney transplant
This project studies blood markers and tissue patterns after kidney transplants to identify which patients are at highest risk of cardiovascular problems.
-
Understanding how BK virus links infection to kidney transplant rejection
This project looks at how BK polyomavirus reactivation affects kidney transplant patients and aims to use pre-transplant T cell information to tailor immunosuppression and monitoring.
-
Characterization of a LILRB3 SNP cluster and its link to kidney transplant outcomes
A study in kidney transplant recipients looks at genetic factors that may be tied to higher risk of graft failure.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.